MOLECULAR DESIGN INTERNATIONAL, INC.

Address

111 HIGHLLANS ST STE159
MEMPHIS, TN, 38112-4417

Information

DUNS: 075592597
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Novel Topical Therapy for Diabetic Retinopathy using Beta-Adrenergic Receptor Ago

    Amount: $108,399.00

    DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal ...

    STTRPhase I2011Department of Health and Human Services
  2. Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

    Amount: $1,196,750.00

    DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degr ...

    SBIRPhase II2008Department of Health and Human Services
  3. Topical Skin Treatment to Facilitate Wound Healing in the Aged Population

    Amount: $100,001.00

    DESCRIPTION (provided by applicant): MDI-301 is a synthetic retinoid. MDI-301, like RA, induces collagen synthesis and reduces expression of collagen-degrading matrix metalloproteinases in the skin. T ...

    SBIRPhase I2008Department of Health and Human Services
  4. Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degra ...

    SBIRPhase I2006Department of Health and Human Services
  5. NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

    Amount: $1,016,500.00

    DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried ou ...

    SBIRPhase II2005Department of Health and Human Services
  6. NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

    Amount: $99,000.00

    DESCRIPTION (provided by applicant): Molecular Design International, Inc. (MDI) has designed and synthesized three synthetic retinoids based on the removal of the free carboxylic acid proton and re ...

    SBIRPhase I2003Department of Health and Human Services
  7. DEVELOPMENT OF MULTI-RECEPTOR LC STATIONARY PHASES

    Amount: $100,000.00

    DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationshi ...

    STTRPhase I2001Department of Health and Human Services
  8. Alpha Adrenergic Agonists for CPR

    Amount: $72,595.00

    In the United States alone, approximately 450,000 people yearly suffer a cardiac arrest outsidethe hospital. Less than 10% of these patients are discharged from the hospital alive, and of these,approx ...

    SBIRPhase I1994Department of Health and Human Services
  9. TOPICAL PRODRUGS FOR THE TREATMENT OF PSORIASIS

    Amount: $500,000.00

    PSORIASIS IS A DISEASE THAT AFFECTS MILLIONS OF AMERICANS WITH CHRONIC RECURRENT EXACERBATIONS AND REMISSIONS THAT AREEMOTIONALLY AND PHYSICALLY DEBILITATING. SEVERAL TREATMENTSARE AVAILABLE, BUT IN M ...

    SBIRPhase II1991Department of Health and Human Services
  10. DEVELOPMENT OF ELASTASE INHIBITORS TO TREAT EMPHYSEMA

    Amount: $50,000.00

    THE GOAL OF THIS PROJECT IS TO DEVELOP A SYNTHETIC INHIBITOR OF ELASTASE THAT WILL BE EFFECTIVE AND SAFE IN THE TREATMENT OF EMPHYSEMA. TWO DIFFERENT LABORATORIES REPORTED THAT CHLOROMETHYL KETONE (CM ...

    SBIRPhase I1991Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government